Ano: 2018

The top-selling drugs of 2018 are set to be a mix of old-timers and newcomers, shows global consensus sales forecast data from EvaluatePharma. The top five products on this forecast list are repeat bestsellers, and AbbVie’s adalimumab held the top slot in both 2016 and 2017. Several of these top earners are likely to come under pressure in upcoming years from biosimilar launches… Para acessar a publicação na íntegra clique aqui Fonte: 86 | FEBRUARY 2018 | VOLUME 17 www.nature.com/nrd…

The top-selling drugs of 2018 are set to be a mix of old-timers and newcomers, shows global consensus sales forecast data from EvaluatePharma. The top five products on this forecast list are repeat bestsellers, and AbbVie’s adalimumab held the top slot in both 2016 and 2017. Several of these top earners are likely to come under pressure in upcoming years from biosimilar launches… Click here to original publication. Fonte: 86 | FEBRUARY 2018 | VOLUME 17 www.nature.com/nrd…

Drug makers in 2017 again faced many of the uncertainties and pressures experienced in 2016, including continued public and political criticism of drug pricing, and the urgency to put the patient and value-based health care at the forefront of medicine… Para acessar a publicação na íntegra clique aqui Fonte: NATURE REVIEWS | DRUG DISCOVERY VOLUME 17 | FEBRUARY 2018 | 91…

But the wandering-spider, or Phoneutria nigriventer, will be soon known for other reason. Biozeus, a private biotechnology company in Rio de Janeiro, is developing a cream for erectile dysfunction based on a peptide found in the spider’s venom. The project is in its last stages with human trials set to begin in a couple of months… Para acessar a publicação na íntegra clique aqui Fonte: BBC.com…

The FDA posted strong approval numbers last year, rebounding from a steep drop in 2016. The agency’s Center for Drug Evaluation and Research (CDER) approved a total of 46 new drugs in 2017, the most since the peak of 59 in 1996 (FIG. 1; TABLE 1). This puts last year’s approval count well above the 5-year and 10-year averages (36 and 32, respectively)… Para acessar a publicação na íntegra clique aqui Fonte: NATURE REVIEWS | DRUG DISCOVERY ADVANCE ONLINE PUBLICATION | 1…

The recent failure of AstraZeneca’s interleukin-13 (IL-13) inhibitor tralokinumab to show  efficacy in two phase 3 trials in asthma extends an already lengthy rap sheet against a therapeutic target that has confounded drug developers’ expectations. Despite widespread recognition of the central role IL-13 plays in mediating allergic disease, companies have struggled for more than a decade to produce clear-cut clinical evidence that targeting the cytokine will benefit patients… Para acessar a publicação na íntegra clique aqui Fonte: NATURE BIOTECHNOLOGY VOLUME 36 NUMBER 1 JANUARY 2018…

VelocityTX and Rio de Janeiro–based Outsource Brazil (OBr) have launched a new program to lure promising tech and biotech businesses from Brazil to San Antonio, Texas… Para acessar a publicação na íntegra clique aqui Fonte: VOLUME 36 NUMBER 1 JANUARY 2018 NATURE BIOTECHNOLOGY…

CRISPR–Cas9-edited plants can be cultivated and sold free from regulation, the US Department of Agriculture (USDA) is making increasingly clear. The agency gave a free pass to Camelina sativa, or false flax, with enhanced omega-3 oil… Para acessar a publicação na íntegra clique aqui Fonte: VOLUME 36 NUMBER 1 JANUARY 2018 NATURE BIOTECHNOLOGY  …

Potential market catalysts in the first quarter of 2018 include important top-line clinical trial results for rigerimod (developed by ImmuPharma and SymBio) for systemic lupus… Para acessar a publicação na íntegra clique aqui Fonte: NATURE REVIEWS | DRUG DISCOVERY VOLUME 17 | JANUARY 2018 …

First in vivo gene-editing drugs enter the clinic Sangamo Therapeutics has started dosing patients with gene-editing drugs that are administered directly into the blood. Para acessar a publicação na íntegra clique aqui Click here to original publication. Fonte: NATURE REVIEWS | DRUG DISCOVERY VOLUME 17 | JANUARY 2018…